Compare LRHC & SXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LRHC | SXTC |
|---|---|---|
| Founded | 2004 | 2005 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7M | 1.8M |
| IPO Year | 2022 | 2017 |
| Metric | LRHC | SXTC |
|---|---|---|
| Price | $1.40 | $1.68 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 1.6M | 19.6K |
| Earning Date | 05-28-2026 | 08-19-2019 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 26.17 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $69,448,786.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 118.67 | N/A |
| 52 Week Low | $0.08 | $0.03 |
| 52 Week High | $11.21 | $6.98 |
| Indicator | LRHC | SXTC |
|---|---|---|
| Relative Strength Index (RSI) | 46.36 | 38.33 |
| Support Level | $0.44 | $1.19 |
| Resistance Level | $2.12 | $1.80 |
| Average True Range (ATR) | 0.29 | 0.10 |
| MACD | -0.08 | -0.05 |
| Stochastic Oscillator | 1.50 | 10.34 |
La Rosa Holdings Corp operates in the U.S. residential real estate market. It is a holding company for agent-centric, technology-integrated, cloud-based, multi-service real estate companies. The company's business is organized based on the services it provides internally to the agents and to the public, which are residential and commercial real estate brokerage, franchising, real estate brokerage education and coaching, and property management. The company has six reportable segments, namely: Real Estate Brokerage Services (Residential), Franchising Services, Coaching Services, Property Management, Real Estate Brokerage Services (Commercial), and Title Settlement and Insurance. It derives maximum revenue from the Real Estate Brokerage Services (Residential) segment.
China SXT Pharmaceuticals Inc is a pharmaceutical company that is focused on the research, development, manufacture, marketing, and sales of Traditional Chinese Medicine Pieces (TCMP), particularly, TCMP (Directed-oral TCMP, and After-soaking TCMP) which is a sort of Traditional Chinese Medicine (TCM) that has been processed to be ready for use without decoction. Geographically, the firm generates its revenue from the People's Republic of China.